[Form 4] Hims & Hers Health, Inc. Insider Trading Activity
Patrick Harrison Carroll, a director and the company's Chief Medical Officer at Hims & Hers Health, Inc. (HIMS), reported a sale of 10,021 shares of Class A common stock on 09/17/2025 at a price of $50.50 per share. After the transaction he beneficially owned 169,940 shares, reported as direct ownership. The filing states the sales were executed under a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2025. The Form 4 was signed by an attorney-in-fact on 09/19/2025. The filing discloses the insider relationship and the exact transaction details without additional commentary.
Patrick Harrison Carroll, direttore e Chief Medical Officer della società Hims & Hers Health, Inc. (HIMS), ha riportato una vendita di 10.021 azioni ordinarie di Classe A il 17/09/2025 a un prezzo di 50,50 $ per azione. Dopo la transazione deteneva direttamente 169.940 azioni. La dichiarazione indica che le vendite sono state eseguite nell’ambito di un piano di negoziazione Rule 10b5-1 adottato dall’interessato il 19/05/2025. Il modulo 4 è stato firmato da un procuratore-in-fatto il 19/09/2025. La dichiarazione rivela la relazione di insider e i dettagli esatti della transazione senza commenti aggiuntivi.
Patrick Harrison Carroll, director y Director Médico de la empresa Hims & Hers Health, Inc. (HIMS), informó la venta de 10,021 acciones ordinarias de Clase A el 17/09/2025 a un precio de $50,50 por acción. Tras la operación, poseía de forma beneficiosa 169,940 acciones, reportadas como propiedad directa. El escrito indica que las ventas se realizaron bajo un plan de negociación Rule 10b5-1 adoptado por la persona reportante el 19/05/2025. El Formulario 4 fue firmado por un apoderado en calidad de poder el 19/09/2025. La presentación divulga la relación de insider y los detalles exactos de la operación sin comentarios adicionales.
패트릭 해리슨 캐롤은 Hims & Hers Health, Inc. (HIMS)의 이사이자 최고 의료 책임자(CMO)로서 2025년 9월 17일에 주당 50.50달러에 A클래스 보통주 10,021주를 매도했다고 보고했습니다. 거래 후 그는 직접 소유로 169,940주를 보유하게 되었습니다. 제출서에는 매도가 보고자 2025년 5월 19일에 채택된 Rule 10b5-1 거래 계획에 따라 실행되었다고 명시되어 있습니다. Form 4는 2025년 9월 19일에 대리인에 의해 서명되었습니다. 제출서는 내부자 관계 및 거래의 정확한 세부 정보를 추가 해설 없이 공개합니다.
Patrick Harrison Carroll, directeur et Chief Medical Officer de Hims & Hers Health, Inc. (HIMS), a déclaré une vente de 10 021 actions ordinaires de classe A le 17/09/2025 à un prix de 50,50 $ par action. Après la transaction, il détenait de manière bénéficiaire 169 940 actions, déclarées comme propriété directe. Le dossier indique que les ventes ont été réalisées dans le cadre d’un plan de négociation Rule 10b5-1 adopté par la personne déclarant le 19/05/2025. Le Formulaire 4 a été signé par un mandataire le 19/09/2025. Le dossier révèle la relation d’initié et les détails exacts de la transaction sans commentaire supplémentaire.
Patrick Harrison Carroll, Director und Chief Medical Officer von Hims & Hers Health, Inc. (HIMS), meldete den Verkauf von 10.021 Stammaktien der Klasse A am 17.09.2025 zu einem Preis von 50,50 USD pro Aktie. Nach der Transaktion hielt er direkt 169.940 Aktien. Die Einreichung gibt an, dass die Verkäufe im Rahmen eines Rule 10b5-1-Handelsplans durchgeführt wurden, der von der meldenden Person am 19.05.2025 angenommen wurde. Das Formular 4 wurde von einem Bevollmächtigten am 19.09.2025 unterschrieben. Die Einreichung offenbart die Insider-Beziehung und die genauen Transaktionsdetails ohne zusätzliche Kommentare.
باتريك هاريسون كارول، مدير ومسؤول الرعاية الطبية التنفيذي في شركة Hims & Hers Health, Inc. (HIMS)، أبلغ عن بيع 10,021 سهمًا عاديًا من الفئة A في 17/09/2025 بسعر 50.50 دولارًا للسهم. بعد الصفقة، امتلك حصة مباشرة من 169,940 سهمًا. تفيد الوثائق أن البيعات تمت بموجب خطة تداول Rule 10b5-1 اعتمدها الشخص المبلغ في 19/05/2025. تم توقيع النموذج 4 بواسطة وكيل مفوض في 19/09/2025. تكشف الوثائق عن العلاقة بين الداخلين وتفاصيل الصفقة الدقيقة دون تعليق إضافي.
帕特里克·哈里森·卡罗尔,作为 Hims & Hers Health, Inc.(HIMS)的董事兼首席医疗官,报告在 2025 年 9 月 17 日以每股 50.50 美元的价格出售了 10,021 股 A 类普通股。交易后,他直接持有 169,940 股。备案显示销售是在报告人于 2025 年 5 月 19 日通过的 Rule 10b5-1 交易计划下执行的。Form 4 由授权代理人在 2025 年 9 月 19 日签署。该备案披露了内部关系及交易的确切细节,未作额外评论。
- Transaction fully disclosed with date, price, quantity, and post-transaction holdings
- Sale executed under a Rule 10b5-1 trading plan, indicating a prearranged framework for trades
- Reporting person identified as Director and Chief Medical Officer, clarifying insider status
- Reduction of direct holdings by 10,021 shares as of 09/17/2025
- Sale price $50.50 realized on the disposed shares (cash proceeds implied but not stated explicitly)
Insights
TL;DR Insider sold 10,021 shares at $50.50 under a prearranged 10b5-1 plan; remaining direct holding is 169,940 shares.
The sale is clearly documented with transaction date, price, and post-transaction holdings, which supports transparency for market monitoring. The use of a 10b5-1 plan indicates the trades were pre-authorized, reducing the likelihood they were based on material non-public information. The filing does not provide information on the percentage of outstanding shares or any change in role or compensation.
TL;DR Form 4 properly discloses insider status, transaction details, and reliance on a 10b5-1 plan, meeting disclosure expectations.
The report identifies the reporting person as both a director and officer and specifies the nature of the transaction and plan adoption date. Signature by an attorney-in-fact is noted. The filing contains no governance concerns beyond the disclosed sale; it does not report amendments or additional arrangements.
Patrick Harrison Carroll, direttore e Chief Medical Officer della società Hims & Hers Health, Inc. (HIMS), ha riportato una vendita di 10.021 azioni ordinarie di Classe A il 17/09/2025 a un prezzo di 50,50 $ per azione. Dopo la transazione deteneva direttamente 169.940 azioni. La dichiarazione indica che le vendite sono state eseguite nell’ambito di un piano di negoziazione Rule 10b5-1 adottato dall’interessato il 19/05/2025. Il modulo 4 è stato firmato da un procuratore-in-fatto il 19/09/2025. La dichiarazione rivela la relazione di insider e i dettagli esatti della transazione senza commenti aggiuntivi.
Patrick Harrison Carroll, director y Director Médico de la empresa Hims & Hers Health, Inc. (HIMS), informó la venta de 10,021 acciones ordinarias de Clase A el 17/09/2025 a un precio de $50,50 por acción. Tras la operación, poseía de forma beneficiosa 169,940 acciones, reportadas como propiedad directa. El escrito indica que las ventas se realizaron bajo un plan de negociación Rule 10b5-1 adoptado por la persona reportante el 19/05/2025. El Formulario 4 fue firmado por un apoderado en calidad de poder el 19/09/2025. La presentación divulga la relación de insider y los detalles exactos de la operación sin comentarios adicionales.
패트릭 해리슨 캐롤은 Hims & Hers Health, Inc. (HIMS)의 이사이자 최고 의료 책임자(CMO)로서 2025년 9월 17일에 주당 50.50달러에 A클래스 보통주 10,021주를 매도했다고 보고했습니다. 거래 후 그는 직접 소유로 169,940주를 보유하게 되었습니다. 제출서에는 매도가 보고자 2025년 5월 19일에 채택된 Rule 10b5-1 거래 계획에 따라 실행되었다고 명시되어 있습니다. Form 4는 2025년 9월 19일에 대리인에 의해 서명되었습니다. 제출서는 내부자 관계 및 거래의 정확한 세부 정보를 추가 해설 없이 공개합니다.
Patrick Harrison Carroll, directeur et Chief Medical Officer de Hims & Hers Health, Inc. (HIMS), a déclaré une vente de 10 021 actions ordinaires de classe A le 17/09/2025 à un prix de 50,50 $ par action. Après la transaction, il détenait de manière bénéficiaire 169 940 actions, déclarées comme propriété directe. Le dossier indique que les ventes ont été réalisées dans le cadre d’un plan de négociation Rule 10b5-1 adopté par la personne déclarant le 19/05/2025. Le Formulaire 4 a été signé par un mandataire le 19/09/2025. Le dossier révèle la relation d’initié et les détails exacts de la transaction sans commentaire supplémentaire.
Patrick Harrison Carroll, Director und Chief Medical Officer von Hims & Hers Health, Inc. (HIMS), meldete den Verkauf von 10.021 Stammaktien der Klasse A am 17.09.2025 zu einem Preis von 50,50 USD pro Aktie. Nach der Transaktion hielt er direkt 169.940 Aktien. Die Einreichung gibt an, dass die Verkäufe im Rahmen eines Rule 10b5-1-Handelsplans durchgeführt wurden, der von der meldenden Person am 19.05.2025 angenommen wurde. Das Formular 4 wurde von einem Bevollmächtigten am 19.09.2025 unterschrieben. Die Einreichung offenbart die Insider-Beziehung und die genauen Transaktionsdetails ohne zusätzliche Kommentare.